US move to shorten COVID-19 isolation stirs confusion, doubt
WASHINGTON — U.S. health officials’ decision to shorten the recommended COVID-19 isolation and quarantine period from 10 days to five is drawing criticism from some medical experts and could create more confusion and fear among Americans.
Start Free AccountGet access to 10 premium stories every month for FREE!
Already a Subscriber?Current print subscriber? Activate your complimentary Digital account.
Subscribe NowChoose a package that suits your preferences.
Hello all aloha, i am going to share that the CDC has withdrawn the PCR tests back in july officially on Dec 31,2021. you can look up this on cdc website. they have been giving way too many false positives because the cycles were set over 45. this is how they built this hysteria through false positives also they have admitted that it would read up to 12 weeks you will continue to test positive. why is people testing negative monday positive tuesday and negative wenesday? Pharmaceutical industry surely made a lot of money off of people.
” Audience: Individuals Performing COVID-19 Testing
Level: Laboratory Alert
After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.
Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.”